Tim Lenehan Corporate VP, Global Head of Market Access Novo Nordisk
Marie-Sharmila Blandino Global Access Strategy Lead, Oncology Amgen
Ramiro E Gilardino Global HTA & Access Policy Lead MSD
Herve Lilliu Founder and Director Inbeeo
Jason Foster Chief Executive Officer Ori Biotech
Paul Simms Chief Executive Impatient Health
Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. When it comes to achieving your price and volume targets, we’re playing a new game with new rules.
This webinar is designed to help you uncover strategic frameworks, tailored for ATMP access challenges. Only then will you be able to define a access strategy that is right for your asset. And as a new generation of ATMPs are unleashed, these frameworks will help you fight for a differentiated proposition – and win.
Undoubtedly you’ll be grappling with fresh challenges around cost, manufacturing, development, trials, size of population, administration and drug delivery. And so the equation has become more complex. Throw in the enormous burden that healthcare organisations are facing as they struggle to organise themselves around multiple new therapy regimens, against the reality of Covid-induced backlogs and deficits, and you have a great deal more factors to try and contain.
Without an intelligent approach you’ll quickly find yourself sinking rather than swimming. Our panellists will show you how to keep your head above water.